Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436.

Cancers (Basel) · 2021 · PMC8582601 · PMID 34771451

Europe PMC DOI

hedged sentence

0.0400

closest p · 0.8× alpha

0.0400

boldest claim

The sentences

borderline significantp = 0.04actually significant

63.3 ± 2.3 years (Median: 65.0 years), which was borderline significant ( p = 0.04).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.